Contributors: Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa); Instituto de Investigación Biomédica de A Coruña La Corogne, Espagne (INIBIC); A Coruña University Hospital La Corogne, Espagne; Department of Medical Microbiology, Amerikan Hastanesi, Istanbul, Turkey; CHU UCL Namur; Hospital Universitario Ramón y Cajal Madrid; Universidad de Alcalá - University of Alcalá (UAH); University of Oldenburg; Erasmus University Medical Center Rotterdam (Erasmus MC); Karolinska Institutet Stockholm; Karolinska University Hospital Stockholm; Institut de Chimie des Substances Naturelles (ICSN); Institut de Chimie - CNRS Chimie (INC-CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS); Växjö Central Hospital; Semmelweis University Budapest; Universität Bern = University of Bern = Université de Berne (UNIBE); Universiteit Antwerpen = University of Antwerpen Antwerpen; Instituto Maimonides de Investigación Biomédica de Cordoba (IMIBIC); Universidad de Córdoba = University of Córdoba Córdoba -Hospital Universitario Reina Sofía; Università degli studi di Verona = University of Verona (UNIVR); Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT); CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth); Université de Limoges (UNILIM)-Université de Limoges (UNILIM); Team Resist Le Kremlin-Bicêtre; Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; National Institute for Public Health and the Environment Bilthoven (RIVM); Instituto de Salud Carlos III Madrid (ISCIII); University Hospital of North Norway Tromsø (UNN); University of Ljubljana; University of Trás-os-Montes and Alto Douro Portugal (UTAD); Université de Fribourg = University of Fribourg (UNIFR); National and Kapodistrian University of Athens (NKUA); The Arctic University of Norway Tromsø, Norway (UiT); University of Zagreb; Tsaritsa Yoanna University Hospital = Queen Giovanna University Hospital Sofia; Lithuanian University of Health Science (LUSH); Laboratoire Chrono-environnement (UMR 6249) (LCE); Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC); Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC); European Project: 952491 ,AmReSu
نبذة مختصرة : International audience ; ScopePseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult to treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles.MethodsTo address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) launched the “Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe” (ISARPAE) initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance (JPIAMR) network call and included a panel of over 40 researchers from 18 European Countries. Thus, an ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members.Questions addressed in the position paperTo provide an update on (i) the emerging resistance mechanisms to classical and novel antipseudomonal agents, with a particular focus on β-lactams, (ii) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (iii) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles and ...
Processing Request
No Comments.